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httcense.Abstract Purpose: The purpose of this study was to evaluate the role of integrated PET/CT in the
staging of lung cancer compared with CT alone or PET alone.
Materials and methods: Thirty-three patients underwent integrated PET/CT for the staging of lung
cancer. The tumor, node and metastasis (TNM) stages were assessed with CT, PET and integrated
PET–CT and compared with the surgical and pathological staging.
Results: CT correctly evaluated the (T) status in (64%) of the patients, PET in (59%) and PET/CT
in (86%). CT correctly evaluated the (N) status in (73%) of the patients, PET in (76%), and PET/
CT (88%) with accuracy, sensitivity, speciﬁcity, PPV and NPV were 73%, 78%, 71%, 50% and
94% for CT, 76%, 67%, 79%, 55% and 95% for PET and 88%, 89%, 88%, 73% and 100%
for PET/CT respectively, and for (M) status were 91%, 86%, 92%, 75% and 96% for CT, 88%,
71%, 92%, 71% and 92% for PET and 97%, 100%, 96%, 88% and 100% for PET/CT respectively.
Regarding the overall TNM staging CT correctly staged 24 patients. PET correctly staged 23 cases
while PET/CT correctly staged 30 cases. A signiﬁcant difference in the accuracy of overall tumor
staging between PET/CT and CT (P= 0.0412) or PET (P= 0.0233).
Conclusion: The integrated PET/CT is superior to either CT or PET in the staging of lung cancer
which has an important impact on selection of the appropriate treatment regimen.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Lung cancer is the most common cancer in the world and is the
leading cause of cancer related death in many countries (1,2).
Accurate staging of lung cancer is mandatory to choose the
optimal treatment and to select patients who are likely to
beneﬁt from surgery (3–5). Staging of lung cancer is based
on accurate determination of the tumor size, inﬁltration ofProduction and hosting by Elsevier B.V.
.09.007
Fig. 1 Sixty-two year old male with left upper lobe cancer. Axial CT (a) shows a large soft tissue mass lesion at the apico-posterior
segment of the left upper lobe which is continuous with the pleura with suspected chest wall involvement. Suspected encasement of the
proximal part of the left subclavian artery is also noted. Axial PET at the same level (b) shows increased FDG uptake of a little smaller
area than the lesion seen in CT with suspected chest wall involvement. Axial (c) and coronal (d) integrated PET/CT showing FDG uptake
of the mass which can be differentiated from the adjacent atalectasis with no FDG uptake, chest wall involvement and left subclavican
encasement are present.
614 M.A. El-Hariri et al.the contiguous structures, the presence or absence of satellite
nodules, the involvement of hilar and mediastinal lymph nodes
and the presence of distant metastasis. Tumor, node, metasta-
sis (TNM) staging, as deﬁned by the American Joint Commit-
tee on Cancer (AJCC), is a very important tool not only to
determine the prognosis but also to choose the most appropri-
ate therapy for patients with lung cancer (6–9).
Conventional chest radiography, computed tomography
(CT), magnetic resonance imaging, radionuclide scintigraphy,
and positron emission tomography (PET) have all been used
for the staging of lung cancer (10).
Computed tomography (CT) is most frequently used in the
suspected lung tumors. It gives imaging information about the
localization and the extent of the tumor, the presence of en-
larged lymph nodes and the presence of metastatic disease
but it is limited by the inability to distinguish between benign
and malignant disease entities (11,12). Theoretically, one could
perform CT of the head, neck, chest, abdomen, pelvis, and
even the extremities, to stage lung cancer. However, this is
not a reasonable approach because of excessive radiation
exposure, expense, and the use of scanner time. Obviously,
the chest must be scanned for complete evaluation of the pri-
mary lung tumor and for assessment of hilar and mediastinal
lymph node involvement and thoracic metastases (13).
Positron emission tomography (PET) with the glucose
analog 2-18F-ﬂuoro-2-deoxy-D-glucose (FDG) is based on theenhanced glucose metabolism of lung cancer cells. FDG
undergoes the same uptake as glucose but it is metabolically
trapped and accumulated in the cancer cell after phosphoryla-
tion by hexokinase. Reading of the FDG distribution in the
body by the PET camera allows differentiation between nor-
mal and malignant tissues and improves identiﬁcation of nodal
involvement, distant metastases, and early tumor recurrence
(14–17). However, the relatively poor spatial resolution, the
low contrast between different tissues and the blurring due
to motion and partial volume effects in small foci can result
in difﬁculties to localize lesions that show pathologic FDG up-
take. Furthermore, false-positive FDG uptake is seen in
inﬂammatory conditions such as bacterial pneumonia. On
the other hand false-negative results can occur in lesions smal-
ler than 1 cm because a critical mass of metabolically active
malignant cells is required for PET diagnosis. Some tumor tis-
sues also show no or little FDG uptake, like biologically weak
tumors such as bronchoalveolar cell carcinoma (14,18–20).
Combining detailed anatomical information obtained by
CT with the metabolic information obtained by FDG-PET
in PET/CT enables more accurate characterization of pulmon-
ary lesions that are indeterminate on CT, more accurate
staging of lung cancer and this in turn frequently alters the
management strategy, reduces the number of futile thoracoto-
mies and provides important prognostic information (21–26).
PET and CT can be combined using different techniques.
Fig. 2 Seventy-six year old female with left lung cancer. Axial CT (a) shows soft tissue density mass lesion at the apico-posterior segment
of the left upper lobe associated with right pectoral lymph node as well as suspected retrocaval lymph node. Axial PET (b) and PET/CT (c)
at the same level show increased FDG uptake of the lung mass which is a little smaller in size than that seen in CT due to the central area
of breakdown with no FDG uptake associated with increased FDG uptake of the right pectoral and retrocaval lymph nodes.
Integrated PET/CT in the preoperative staging of lung cancer 615The integrated PET/CT study using a single machine provides
the best co-registration of physiologic and anatomic details
(6).
The purpose of this study is to evaluate the role of inte-
grated PET/CT in the staging of lung cancer in comparison
with CT alone or PET alone.
2. Patients and methods
2.1. Patients
Thirty-three patients (28 men and ﬁve women) having lung
cancer with a median age of 64 years (range 34–76 years) were
included in our study. They underwent whole body integrated
PET/CT imaging for staging lung lesions in the period from
September 2010 till December 2011. CT, PET, and combined
PET/CT data were evaluated separately for staging of the
primary tumor (T), regional lymph nodes (N) and distant
metastasis (M). Imaging ﬁndings were compared with histopa-
thological ﬁndings (Gold standard). Institutional review board
approval and informed consent was taken from all patients.
2.2. PET/CT imaging
Combined PET/CT imaging was conducted by using the Sie-
mens medical solution system (Siemens biograph 64 PET/CT
scanner). The CT component of the biograph corresponds to
a Somatom sensation 64 section (Siemens Medical Solutions).
CT images were acquired with 130 mAs, 130 kV and slice
thickness of 5 mm. The scanning area for CT and PET was de-
ﬁned on a CT topogram with a ﬁeld of view from the head to
the middle thigh. To ensure diagnostic CT image quality,
120 ml of iodinated contrast agent was administered intrave-
nously using an automated injector. CT was performed during
breath-hold at expiration tidal volume. This limitedbreath-hold technique was used to avoid respiration artifacts
on the CT images and for a good matching between the CT
and the PET images.
The PET component of the combined PET/CT tomography
is based on an ECAT ACCEL Siemens Medical Solutions), a
full-ring Lutetium ortho silicate (LSO)-based PET system with
an in-plane spatial resolution of 4.6 mm and an axial ﬁeld of
view of 15.5 cm for each bed position. PET imaging was per-
formed 60 min after the administration of 300 MBq (about 8
mci) of FDG by multiple overlapping bed positions (5 min
per bed position). Patients rested in the supine position during
the tracer uptake phase to avoid muscular tracer accumula-
tion. Attenuation correction was based on the CT data.
Patients had been instructed to fast for 6 h prior to starting
the examination. Blood samples collected before the injection
of the radioactive tracer ensured blood glucose levels in the
normal range.
3. Imaging data analysis
3.1. CT images
CT staging was done using the CT images obtained from the
integrated PET/CT scanner. The radiologist was asked to as-
sign a T, N, and M status of the tumor using the 7th edition
of the AJCC (The American Joint Committee on Cancer)
TNM system for the classiﬁcation of lung cancer. Tumor
assessment was based on lesion size and localization, its
relation to the surrounding structures and chest wall and the
distance of the primary tumor from the carina. Lymph node
assessment was based on its size. Lymph nodes with a short
axis diameter greater than 10 mm were considered positive.
Assessment of the M status for lung, liver, adrenal glands,
brain, bone and other organs was performed using criteria
such as size, localization and contrast enhancement.
Fig. 3 Sixty-three year old male with right lung cancer. Axial CT
(a) shows a soft tissue density mass lesion at the posterior segment
of the right middle lobe and the tumor was staged as T2 tumor. On
axial PET (b) and axial integrated PET /CT (c) the area of increased
FDGuptake is greater than the lesion seen in CT and the tumor was
staged as T3. FDG uptake was also detected in the sternum and the
vertebral body at PET and PET/CT (M1-stage IV).
Fig. 4 Pulmonary metastasis: 69 year old female with right lung
cancer. Axial CT mediastinal and lung window (a,b) show small
peripherally located pulmonary nodule at the anterior segment of
the left lower lobe. Minimal pleural thickening/effusion is noted at
the right lung. Axial integrated PET/CT (c) at the same level
shows increased FDG uptake of the left pulmonary nodule which
is conﬁrmed by follow up.
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PET images were assessed qualitatively for regions of focally
increased FDG uptake, as well as quantitatively by determin-
ing standardized uptake values. An increase in FDG uptake to
a level greater than that in the surrounding tissue at qualitative
analysis and a standard uptake value of more than 2.5 were
considered to characterize malignancy. T, N and M status of
each patient was assessed using the AJCC TNM system.
3.3. Integrated PET/CT images
Fused PET/CT images were evaluated to assign the T, N and
M status of each patient using the AJCC TNM system. Tumorstaging was performed as in CT. A lesion suggestive of a
primary tumor on CT but negative on PET was considered
positive, and a lesion not suggestive on CT but positive on
PET was considered positive for tumor on integrated PET/
CT. Lymph nodes with increased FDG uptake were consid-
ered positive for metastatic spread even when they were smal-
ler than 1 cm in short-axis diameter. PET negative lymph
nodes were considered as benign, even when they were larger
than 1 cm in short-axis diameter. Concerning distant metasta-
sis (M) pulmonary nodules suggestive for lung metastases on
CT but negative at PET were considered as lung metastases.
Lesions in the liver, spleen and brain suspicious of metastases
Fig. 5 Splenic metastasis: 71 year old male with lung cancer.
Axial CT (a) shows a well deﬁned hypodense focal splenic lesion.
Axial PET (b) at the same level shows no FDG uptake at the
lesion site. Axial integrated PET/CT at the same level (c) shows no
FDG uptake of the lesion. Follow up ﬁndings in this patient
conﬁrmed the diagnosis.
Fig. 6 Bone metastasis. Sixty-four year old male with lung
cancer. Axial CT (a) shows osteolytic and sclerotic lesions at one
of the thoracic spines and the adjacent articulating right rib. Axial
PET (b) and integrated PET/CT (c) at the same level show
increased FDG uptake of the lesions.
Integrated PET/CT in the preoperative staging of lung cancer 617on PET or CT were considered as positive for metastases. An
enlarged adrenal gland on CT but negative at PET was consid-
ered as negative. Mediastinal hotspots on PET but without a
visible lesion on CT were considered as negative on integrated
PET/CT.
3.4. Surgical and histopathological analysis
Tumor resection and mediastinal lymph node dissection were
performed in 22 patients. Surgery was performed within a
maximum of 10 days after imaging. The surgeon sampled all
visible and palpable lymph nodes that were accessible in the
hilum and mediastinum. A pathologist assessed the primary
tumor regarding the histopathological type, size, invasion ofthe surrounding structures and the distance from the resection
margin and the location of the involved lymph nodes. Speci-
mens were stained with hematoxylin and eosin and examined
with light microscopy. Surgical and pathological staging for
the tumor (T) and the lymph node (N) was done for these 22
patients. The remaining 11 patients underwent mediastinos-
copy for lymph node staging. Veriﬁcation of distant metastasis
stage (M stage) was done by biopsy or radiological follow up
(for 5–7 months).
3.5. Statistical analysis
Statistical analysis was performed using specialized software
(SPSS for Windows v10). Analysis for the tumor (T stage),
lymph nodes (N stage), and metastases (M stage) with CT
Fig. 7 Bone metastasis. Sixty-seven year old male with lung
cancer. Axial CT (a) shows suspected osteolytic bony lesion at the
left femoral head. Axial PET (b) and integrated PET/CT (c) at the
same level show increased FDG uptake of both acetabulai and
both femoral heads.
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compared with the pathological staging which was used as the
standard of reference. The sensitivities, speciﬁcities, positive
predictive values (PPV), negative predictive values (NPV)
and accuracies of the three different imaging techniques inTable 1 Primary tumor (T) staging in CT, PET and PET/CT in co
Pathological stage Number CT
T0 T1 T2 T3 T4
T1 6 0 4 1 1 0
T2 12 0 3 8 1 0
T3 3 0 0 2 1 0
T4 1 0 0 0 0 1
Total 22the assessment of the T, N, and M stages and of the TNM sys-
tem stage were calculated. The accuracies of the three different
imaging techniques were compared by McNemar’s test.
4. Results
Thirty-three patients (28 men and ﬁve women) having lung
cancer with a median age of 64 years were included in our
study. Twenty-two patients underwent surgical resection and
staging. The remaining 11 patients underwent mediastinoscopy
and lymph node biopsy. Representative cases are seen in (Figs.
1–7). CT correctly evaluated the primary tumor (T) status in
14 of 22 patients (64%), under staged 5 patients and over
staged three patients. PET correctly staged 13 patients
(59%), under staged 3 patients and over staged six patients
while PET/CT correctly staged 19 patients (86%) and under
staged three patients (Tables 1 and 2).
CT correctly evaluated the lymph node involvement in 24
of 33 patients (73%), under staged 2 patients and over staged
7 patients. PET correctly staged 25 patients (76%), under
staged two patients and over staged six patients while PET/
CT correctly staged 29 patients (88%), under staged one
patient and over staged three patients (Tables 3 and 4).
The accuracy, sensitivity, speciﬁcity, PPV and NPV for the
detection of malignant lymph nodes were 73%, 78%, 71%,
50% and 94% for CT, 76%, 67%, 79%, 55% and 95% for
PET and 88%, 89%, 88%, 73% and 100% for PET/CT
respectively.
Distant metastases were detected in seven cases; one to the
brain, four to bone, one to the spleen and one to the lung (Ta-
ble 5). CT correctly detected six cases (true positive) but could
not detect one case to the bones (false negative). On the other
hand it had two false positive cases (one to the lung and one to
the adrenal). PET correctly detected ﬁve cases (true positive)
but could not detect two cases (false negative); one to the brain
and the other to the spleen, while it had two false positive cases
(one to the lung and one to the colon). PET/CT correctly de-
tected the seven cases (true positive) and had one false positive
case to the lung.
The accuracy, sensitivity, speciﬁcity, PPV and NPV for the
detection of distant metastases were 91%, 86%, 92%, 75%
and 96% for CT, 88%, 71%, 92%, 71% and 92% for PET
and 97%, 100%, 96%, 88% and 100% for PET/CT
respectively.
Overall TNM staging was done for all cases. Twenty-two
cases underwent surgical staging for the primary tumor, two
cases were histopathologically proven N2 without distant
metastasis (stage IIIa), two cases were N3 without distant
metastasis (stage IIIb) and seven cases with distant metastasis
(stage IV). CT alone correctly staged 24 patients (73%), over
staged ﬁve cases and under staged four cases. PET alonemparison with pathological staging.
PET PET/CT
T0 T1 T2 T3 T4 T0 T1 T2 T3 T4
0 4 2 0 0 0 6 0 0 0
0 1 8 3 0 0 2 10 0 0
0 0 1 1 1 0 0 1 2 0
0 0 0 1 0 0 0 0 0 1
Table 2 Agreement of CT, PET and PET/CT with pathological staging in primary tumor (T) staging.
Pathological
stage
Number CT PET PET/CT
Agreement Under
staging
Over
staging
Agreement Under
staging
Over
staging
Agreement Under
staging
Over
staging
T1 6 4 0 2 4 0 2 6 0 0
T2 12 8 3 1 8 1 3 10 2 0
T3 3 1 2 0 1 1 1 2 1 0
T4 1 1 0 0 0 1 0 1 0 0
Total 22 14 5 3 13 3 6 19 3 0
Table 3 Lymph node (N) staging in CT, PET and PET/CT in comparison with pathological staging.
Pathological stage Number CT PET PET/CT
N0 N1 N2 N3 N0 N1 N2 N3 N0 N1 N2 N3
N0 24 17 3 4 0 19 1 3 1 21 1 2 0
N1 2 0 2 0 0 1 1 0 0 0 2 0 0
N2 5 1 1 3 0 0 1 3 1 0 1 4 0
N3 2 0 0 0 2 0 0 0 2 0 0 0 2
Total 33
Table 4 Agreement of CT, PET and PET/CT with pathological staging in lymph node (N) staging.
Pathological
stage
Number CT PET PET/CT
Agreement Under
staging
Over
staging
Agreement Under
staging
Over
staging
Agreement Under
staging
Over
staging
N0 24 17 0 7 19 0 5 21 0 3
N1 3 3 0 0 2 1 0 3 0 0
N2 5 3 2 0 3 1 1 4 1 0
N3 1 1 0 0 1 0 0 1 0 0
Total 33 24 2 7 25 2 6 29 1 3
Table 5 Distant metastasis (M) staging in CT, PET and PET/CT in comparison with pathological staging.
Pathological stage Number CT PET PET/CT
Agreement Disagreement Agreement Disagreement Agreement Disagreement
M0 26 24(true negative) 2(false positive) 24(true negative) 2(false positive) 25 (true negative) 1(false positive)
M1 7 6(true positive) 1(false negative) 5(true positive) 2(false negative) 7(true positive) 0
Total 33 30 3 29 4 32 1
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under staged three cases. PET/CT correctly staged 30 cases
(91%), over staged one case and under staged two cases. Dif-
ferences in the accuracy of overall tumor staging between PET/
CT and CT (P= 0.0412) and between PET/CT and PET
(P= 0.0233) were signiﬁcant.
5. Discussion
The rationale of accurate preoperative staging of lung cancer is
to choose the optimal treatment. CT is the standard modality
used to assess the intra-thoracic spread but false negative CT
scans have been reported and were related to the presence of
metastasis in normal sized lymph nodes and false positive ﬁnd-
ings have been related to lymph node enlargement due to
benign process. PET is most widely used in thoracic oncologybecause of its superiority over other imaging techniques in
staging nodal and metastatic disease, however, the poor
anatomic details of PET can lead to errors in diagnosis and
staging. To circumvent this problem, CT is combined with
PET to provide spatially matched morphological and func-
tional data. The diagnostic capability of PET/CT in the preop-
erative staging of lung cancer is superior to that of CT alone
and PET alone as it has the advantage of a more accurate
assignment of tumor stage (T stage) and deﬁning the lymph
node stage (N stage) as well as reduction of the number of fu-
tile thoracotomies (3,6,26,27).
In our study integrated PET/CT was better than PET alone
and CT alone in the assessment of the primary tumor stage (T
stage). CT correctly evaluated the tumor (T) stage in 14 of 22
patients (64%), PET correctly staged 13 patients (59%), while
PET–CT correctly staged 19 patients (86%). This is in agree-
620 M.A. El-Hariri et al.ment with an earlier study (28) in which the T stage was accu-
rately determined with PET/CT in 15 of 16 patients while PET
and CT enabled accurate staging in 12 patients. Also this coin-
cides with the study carried out by Wever et al. (29) who
reported that in 43 (86%) patients, integrated PET/CT could
correctly evaluate the T status, while CT was correct in 34
(68%) and PET in 23 (46%). In the study performed by Subedi
et al. (30) T staging at CT was only concordant with the ﬁnal
histology in 42 (58%) patients while PET/CT was concordant
with ﬁnal pathological T stage in 47 patients (64%). In another
study (27) the primary tumor was correctly staged in 84
patients (79%) at CT and in 91 patients (86%) at PET/CT.
This limited ability of PET alone and CT alone in T staging
can be explained as follows, limited spatial resolution and the
lack of depicted anatomic landmarks limit the ability of PET
to enable the assessment of either tumor size or potential inﬁl-
tration of the thoracic wall, mediastinum, or other adjacent
structures. On the other hand, CT frequently does not enable
differentiation of tumor tissue from adjacent structures.
In our study Integrated PET/CT was better than PET alone
and CT alone in the assessment of the lymph node stage (N).
The accuracy, sensitivity, speciﬁcity, PPV and NPV for the
detection of malignant lymph nodes were 88%, 89%, 88%,
73% and 100% for PET/CT versus 73%, 78%, 71%, 50%
and 94% for CT and 76%, 67%, 79%, 55% and 95% for
PET respectively. Our results coincide with several earlier
reports (27–30). In one of these studies, (29) the sensitivity,
speciﬁcity, PPV, NPV and accuracy were respectively 83%,
84%, 75%, 90% and 84% for integrated PET/CT versus
83%, 68%, 60%, 88% and 74% for CT and 83%, 81%,
71%, 89% and 82% for PET. Another study (28) reported that
the sensitivity, speciﬁcity, PPV, NPV and accuracy were respec-
tively 89%, 94%, 89%, 94% and 93% for integrated PET/CT
versus 70%, 59%, 50%, 77% and 63% for CT and 89%,
89%, 80%, 94% and 89% for PET. Fischer et al. (26) showed
that the accuracy of PET/CT in detection of malignant lymph
nodes was superior to CT alone (85% versus 70%). Also Subedi
et al. (30) reported that nodal staging at PET/CT had a higher
sensitivity (74% vs. 53%), speciﬁcity (87% vs. 84%), positive
predictive value (67% vs. 53%), negative predictive value
(90% vs. 84%) and accuracy (84% vs. 76.6%) than CT.
This can be attributed to the fact that the characterization
of N stage on CT images is based on lymph node size. Nodes
greater than 10 mm are considered malignant however some
literatures (31,32) reported that up to 21% of nodes smaller
than 10 mm are malignant, whereas 40% of nodes larger than
10 mm are benign. On the other hand PET can detect malig-
nant nodes but its poor spatial resolution makes it difﬁcult
to reveal the exact location of the metastatic lymph nodes.
In the current study CT was superior to PET and PET/CT
was superior to each of the CT and PET separately in the
detection of distant metastases. The accuracy, sensitivity, spec-
iﬁcity, PPV and NPV were 91%, 86%, 92%, 75% and 96% for
CT versus 88%, 71%, 92%, 71% and 92% for PET and 97%,
100%, 96%, 88% and 100% for PET/CT respectively.
These ﬁndings support the previous study (28) which re-
ported also that CT is superior to PET and PET/CT is superior
to each of the CT and PET separately in the detection of
distant metastases. De Wever et al. (29) reported that inte-
grated PET/CT evaluated the M status correctly in 98% of pa-
tients, while CT alone was correct in 88% and PET in 96% of
patients. Subedi et al. (30) found that PET/CT revealed metas-tasis in 25 (16%) patients in whom CT failed to detect them.
On the other hand another study (33) showed that integrated
PET/CT was only a little better to assess metastatic disease
compared with PET alone (92% versus 87%).
In the current study, integrated PET/CT evaluated the over-
all TNM stage correctly in 91% of the patients, while CT and
PET were correct in respectively 73% and 70% of the patients.
The difference between integrated PET/CT and CT
(P= 0.0412) and PET (P = 0.0233) was signiﬁcant. This coin-
cides with the previous study (28) which showed that of 27 pa-
tients, the overall tumor stage was correctly determined by CT,
PET and PET/CT in 19, 20 and 26 patients respectively. The
differences in the accuracy of overall tumor staging between
PET/CT and CT (P= 0.008) and between PET/CT and PET
(P= 0.031) were statistically signiﬁcant. This is in agreement
with a previous study (29) which reported also that integrated
PET/CT was correct in 70% of the patients, while CT and
PET were correct in 46% and 30% of the patients respectively
and the difference between integrated PET/CT and CT
(P= 0.0153) and PET (P< 0.0001) was signiﬁcant also. Shim
et al. (27) showed that the correct overall staging (tumor and
nodes only) for 106 patients was statistically higher by inte-
grated PET/CT (n= 92: 87%) than CT alone (n= 70: 66%).
The rationale for accurate preoperative staging of lung can-
cer is to choose the optimal treatment, select patients suitable
for surgery and reduce the number of futile thoracotomies (3).
In our study PET/CT over staged only one case and under
staged two cases, CT alone over staged ﬁve cases and under
staged four cases while PET alone over staged 7 cases and un-
der staged three cases. The impact of PET/CT on the treatment
strategy was shown by Subedi et al. (30) who found that 66
(41%) patients had a change in management as a direct result
of PET/CT. The most important change was regarding if to
proceed to surgery or not. As of 102 patients who were initially
planned to undergo surgery, only 64 had the same plan after
PET/CT evaluation.
6. Conclusion
The integrated PET/CT linking the anatomic and functional
information is superior to CT alone or PET alone in the stag-
ing of lung cancer which has an important impact on the selec-
tion of the appropriate treatment regimen.
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